PMID- 17445161
OWN - NLM
STAT- MEDLINE
DCOM- 20070621
LR  - 20071115
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 69 Suppl 1
DP  - 2007 Apr
TI  - Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor 
      component.
PG  - 42-5
AB  - Recognition of recipient human leukocyte antigen (HLA) class I ligand by donor 
      natural killer cell killer immunoglobulin-like receptors (KIR) has been proposed 
      as the basis for donor allograft reactivity against malignancy leading to 
      reduction in posttransplant relapse and higher survival for acute myelogenous 
      leukemia. Analysis of KIR ligand effects in 1770 patients undergoing 
      myeloablative T-replete hematopoietic cell transplantation (HCT) from HLA-matched 
      or mismatched unrelated donors showed that lack of KIR ligand in patients for 
      inhibitory KIR was associated with lower hazards of relapse in leukemia patients 
      with in HLA-mismatched transplants [hazard ratio (HR): 0.061; 95% confidence 
      interval (CI): 0.43-0.85; P-value = 0.004]. Absence of HLA-C group 2 or HLA-Bw4 
      KIR ligands were each associated with lower hazards of relapse (HR: 0.47; 95% CI: 
      0.28-0.79; P-value = 0.004; HR: 0.56; 95% CI: 0.33-0.97; P-value = 0.04, 
      respectively). Based on these analyses, recipient homozygosity for HLA-B or -C 
      epitopes that define KIR ligands is likely to be a predictive factor for leukemia 
      relapse following myeloablative HCT from unrelated donors. KIR genotyping for 
      unrelated donors and recipients will clarify the role of these receptors in 
      transplant outcome.
FAU - Hsu, K C
AU  - Hsu KC
AD  - Adult Allogeneic Blood and Marrow Transplantation Service, Memorial Hospital, 
      Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. hsuk@mskcc.org
FAU - Pinto-Agnello, C
AU  - Pinto-Agnello C
FAU - Gooley, T
AU  - Gooley T
FAU - Malkki, M
AU  - Malkki M
FAU - Dupont, B
AU  - Dupont B
FAU - Petersdorf, E W
AU  - Petersdorf EW
LA  - eng
GR  - AI 49213/AI/NIAID NIH HHS/United States
GR  - AI069197/AI/NIAID NIH HHS/United States
GR  - AI33484/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Disease-Free Survival
MH  - Follow-Up Studies
MH  - HLA-B Antigens/genetics/immunology
MH  - HLA-C Antigens/genetics/immunology
MH  - Hematologic Neoplasms/genetics/*immunology/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Ligands
MH  - Living Donors
MH  - Neoplasm Recurrence, Local/*immunology/therapy
MH  - Receptors, Immunologic/genetics/*immunology
MH  - Receptors, KIR
MH  - Risk Factors
MH  - Survival Rate
MH  - Transplantation, Homologous
EDAT- 2007/04/21 09:00
MHDA- 2007/06/22 09:00
CRDT- 2007/04/21 09:00
PHST- 2007/04/21 09:00 [pubmed]
PHST- 2007/06/22 09:00 [medline]
PHST- 2007/04/21 09:00 [entrez]
AID - TAN759_5 [pii]
AID - 10.1111/j.1399-0039.2006.759_5.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2007 Apr;69 Suppl 1:42-5. doi: 10.1111/j.1399-0039.2006.759_5.x.